153 related articles for article (PubMed ID: 37812238)
1. Transglutaminase 3 suppresses proliferation and cisplatin resistance of cervical cancer cells by inactivation of the PI3K/AKT pathway.
Chen R; Fang T; Liu N; Shi X; Wang J; Yu H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2269-2280. PubMed ID: 37812238
[TBL] [Abstract][Full Text] [Related]
2. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
Duan W; Liu X
Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation.
Zhou K; Wu C; Cheng W; Zhang B; Wei R; Cheng D; Li Y; Cao Y; Zhang W; Yao Z; Zhang X
Cell Death Dis; 2024 Apr; 15(4):252. PubMed ID: 38589352
[TBL] [Abstract][Full Text] [Related]
4. Hsa_circ_CSPP1/MiR-361-5p/ITGB1 Regulates Proliferation and Migration of Cervical Cancer (CC) by Modulating the PI3K-Akt Signaling Pathway.
Yang W; Xie T
Reprod Sci; 2020 Jan; 27(1):132-144. PubMed ID: 32046405
[TBL] [Abstract][Full Text] [Related]
5. Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.
Wang Z; Li F; He S; Zhao L; Wang F
Gene; 2022 Jan; 809():146003. PubMed ID: 34648915
[TBL] [Abstract][Full Text] [Related]
6. TGM3 functions as a tumor suppressor by repressing epithelial‑to‑mesenchymal transition and the PI3K/AKT signaling pathway in colorectal cancer.
Feng Y; Ji D; Huang Y; Ji B; Zhang Y; Li J; Peng W; Zhang C; Zhang D; Sun Y; Xu Z
Oncol Rep; 2020 Mar; 43(3):864-876. PubMed ID: 32020212
[TBL] [Abstract][Full Text] [Related]
7. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis.
Liu K; Xue B; Bai G; Zhang W
Life Sci; 2020 Oct; 259():118277. PubMed ID: 32800832
[TBL] [Abstract][Full Text] [Related]
8. Involvement of elevated ASF1B in the poor prognosis and tumorigenesis in pancreatic cancer.
Wang K; Hao Z; Fu X; Li W; Jiao A; Hua X
Mol Cell Biochem; 2022 Jul; 477(7):1947-1957. PubMed ID: 35362843
[TBL] [Abstract][Full Text] [Related]
9. BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression.
Xu J; Guo Z; Yuan S; Li H
Mol Cell Biochem; 2022 May; 477(5):1541-1553. PubMed ID: 35184257
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
11. A-kinase-interacting protein 1 promotes EMT and metastasis via PI3K/Akt/IKKβ pathway in cervical cancer.
Zhang X; Liu S; Zhu Y
Cell Biochem Funct; 2020 Aug; 38(6):782-791. PubMed ID: 32401379
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
13. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
15. Silencing DTX3L Inhibits the Progression of Cervical Carcinoma by Regulating PI3K/AKT/mTOR Signaling Pathway.
Hu W; Hu Y; Pei Y; Li R; Xu F; Chi X; Mi J; Bergquist J; Lu L; Zhang L; Yang C
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614304
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 transcriptional regulation of RacGAP1 activates the PI3K/AKT signaling pathway to promote the proliferation, migration, and invasion of cervical cancer cells.
Yao H; Li J; Zhou D; Pan X; Chu Y; Yin J
Int J Clin Oncol; 2024 Mar; 29(3):333-344. PubMed ID: 38172354
[TBL] [Abstract][Full Text] [Related]
17. ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway.
Li F; Zhang Z; Wang P; Wen P; Xu Q; Wang Y; Pan P; Ma L
Life Sci; 2019 Sep; 232():116679. PubMed ID: 31340168
[TBL] [Abstract][Full Text] [Related]
18. miR‑519d‑3p/HIF‑2α axis increases the chemosensitivity of human cervical cancer cells to cisplatin via inactivation of PI3K/AKT signaling.
Jiang L; Shi S; Li F; Shi Q; Zhong T; Zhang H; Xia Y
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760204
[TBL] [Abstract][Full Text] [Related]
19. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
20. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
